Fibrocell Science, Inc. Announces Addition of Marc B. Mazur to Board of Directors
EXTON, Pa., April 6 Fibrocell Science, Inc. (OTC Bulletin Board: FCSC), a biotechnology company focused on the development of regenerative cell therapy for aesthetic, medical and scientific applications, announced today that Marc B. Mazur has been appointed to its board of directors, effective April 1, 2010.
Mr. Mazur is the Chairman of Elsworthy Capital Management Ltd., a London-based European equity hedge fund with assets in excess of $100 million. Most recently, he was the CEO of Brevan Howard U.S. Asset Management, the U.S. arm of London-based Brevan Howard, Europe's largest hedge fund. Prior to joining Brevan Howard, Mr. Mazur had been a senior advisor to both Tsinghua Venture Capital Company (a subsidiary of Tsinghua Holdings, the investment arm of Tsinghua University in Beijing) and Think Equity Partners LLC, a San Francisco investment bank focusing on emerging growth companies in biotechnology, software and greentech.
"As a consultant and private investor with more than 25 years of experience in risk management, business development and senior level sales and marketing within the financial services and health care fields, Marc brings great perspective to the Fibrocell Science board of directors," said Chairman and CEO David Pernock. "We look forward to working with him as we seek to secure U.S. Food & Drug Administration (FDA) approval for our lead therapy's (azficel-T) use in the treatment of moderate to severe nasolabial fold wrinkles."
Mr. Mazur began his career in 1984 at Salomon Brothers in London as a Eurobond trader. In 1987 he joined Goldman Sachs as a Vice President in the fixed income division. He was employed by Goldman from 1987 through 1996 on a full-time basis and subsequently as a consultant from 1997 through 1999. In 1997 Mr. Mazur became an independent consultant, managing business development opportunities in the financial services sector for Goldman Sachs and leveraging his expertise in risk and disease management for public and private companies in the healthcare field. Continuing in healthcare, in 1998 Mr. Mazur was named Vice President for strategic business development at CareInsite (subsequently acquired by WebMD). In 2001 Mr. Mazur founded Ambassador Capital Group, a privately held investment and advisory entity providing capital, business development and strategic planning advice to companies in the healthcare, financial services and real estate fields. He has also been an active angel and venture investor in numerous biotechnology and healthcare device start-ups.
Mr. Mazur is an active member of numerous charitable and educational organizations and has served as a board member and advisory board member of numerous public and private companies. He received his B.A. in political science from Columbia University in 1981 and a J.D. from Villanova University in 1984.
About Fibrocell Science, Inc.
Fibrocell Science, Inc. (OTC Bulletin Board: FCSC) is a biotechnology company focused on developing regenerative fibroblast cell therapy for aesthetic, medical and scientific applications. Fibrocell Science is committed to advancing the scientific, medical and commercial potential of autologous skin and tissue, as well its innovative cellular processing technology and manufacturing excellence. For additional information, please visit www.fibrocellscience.com.
All statements in this press release that are not based on historical fact are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and the provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements in this press release include, without limitation, the ability of the Company to secure FDA approval for its lead therapy's (azficel-T) use in the treatment of moderate to severe nasolabial fold wrinkles. While management has based any forward-looking statements contained herein on its current expectations, the information on which such expectations were based may change. These forward-looking statements rely on a number of assumptions concerning future events and are subject to a number of risks, uncertainties, and other factors, many of which are outside of the Company's control, that could cause actual results to materially differ from such statements. Such risks, uncertainties, and other factors include, but are not necessarily limited to, those set forth under Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2009, as updated in "Item 1A. Risk Factors" in the Company's Quarterly Reports on Form 10-Q filed since the annual report. The Company operates in a highly competitive and rapidly changing environment, thus new or unforeseen risks may arise. Accordingly, investors should not place any reliance on forward-looking statements as a prediction of actual results. The Company disclaims any intention to, and undertakes no obligation to, update or revise any forward-looking statements. Readers are also urged to carefully review and consider the other various disclosures in the Company's public filings with the SEC.
SOURCE Fibrocell Science, Inc.
You May Also Like